Table 3.
The meta analysis of TEAEs and SAEs reported in the included RCTs.
| Type | Symptom | No. of studies (n) | Mavacamten group, n/n | Placebo group, n/n | Heterogeneity | RR | 95% CI | p |
| TEAEs | Palpitations | 2 | 8/95 | 5/74 | I2 = 0% | 0.97 | 0.34–2.82 | 0.97 |
| Atrial fibrillation | 2 | 5/95 | 1/74 | I2 = 0% | 2.23 | 0.38–13.13 | 0.38 | |
| Syncope | 2 | 3/67 | 1/75 | I2 = 0% | 3.39 | 0.53–21.65 | 0.20 | |
| Fatigue | 1 | 5/39 | 3/19 | NA | 1.81 | 0.22–3.05 | 0.76 | |
| Dizziness | 1 | 7/39 | 1/19 | NA | 3.41 | 0.45–25.77 | 0.23 | |
| Chest pain | 1 | 2/56 | 3/55 | NA | 0.65 | 0.11–3.77 | 0.64 | |
| SAEs | Atrial fibrillation | 4 | 8/272 | 5/229 | I2 = 0% | 1.06 | 0.34–3.33 | 0.92 |
| Infection | 2 | 2/179 | 2/183 | I2 = 0% | 0.97 | 0.14–6.56 | 0.98 | |
| Renal failure | 1 | 1/39 | 0/19 | NA | 1.50 | 0.06–35.19 | 0.80 |
RR, risk ratios; CI, confidence interval; TEAEs, total emergent adverse events; SAEs, serious adverse events; RCTs, randomized controlled trials; NA, not applicable.